NR566 Week 1 Questions
And Answers 100% Correct
Biophosphonates - ANSWER Inhibit normal & abnormal bone resorption which increases bone
mineral density. GI & esophageal irritation. Caution: Renal impairment, HF, liver disease & GI
problems.
Insulin dosing - ANSWER 0.3 to 0.5 units/KG/day in divided doses
Lowers glucose 20-60 mg/dl
Lower needs during honeymoon phase or physical activity
Incretins Drugs - ANSWER exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia),
alogliptin (Nesina) & linagliptin (Tradjenta)
Biophosphonates Drugs, SE & Interactions - ANSWER Alendronate (fosamax), Risedronate (actonel),
Ibandronate (boniva)
Antithyroid Agents Contraindications & Interaction - ANSWER Pregnancy (Cat. D.)
Interaction: Lithium & Warfarin
Hypothyroidism Drugs - ANSWER Levothyroxine, Liothyronine & Liotrix
Biguanides - ANSWER Metformin (Glucophage)
1st line therapy for most type 2 DM
Add 2nd drug if target not met in three months
Thiazolidinediones (TZDs) - ANSWER Pioglitazone (Actos), Rosiglitazone (Avandia)
ADRs: WT gain, edema, HF
Glucagon-like peptide 1 (GLP-1) - ANSWER released in small intestine; decreases appetite
ADRs: WT loss & low hypoglycemia risk
And Answers 100% Correct
Biophosphonates - ANSWER Inhibit normal & abnormal bone resorption which increases bone
mineral density. GI & esophageal irritation. Caution: Renal impairment, HF, liver disease & GI
problems.
Insulin dosing - ANSWER 0.3 to 0.5 units/KG/day in divided doses
Lowers glucose 20-60 mg/dl
Lower needs during honeymoon phase or physical activity
Incretins Drugs - ANSWER exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia),
alogliptin (Nesina) & linagliptin (Tradjenta)
Biophosphonates Drugs, SE & Interactions - ANSWER Alendronate (fosamax), Risedronate (actonel),
Ibandronate (boniva)
Antithyroid Agents Contraindications & Interaction - ANSWER Pregnancy (Cat. D.)
Interaction: Lithium & Warfarin
Hypothyroidism Drugs - ANSWER Levothyroxine, Liothyronine & Liotrix
Biguanides - ANSWER Metformin (Glucophage)
1st line therapy for most type 2 DM
Add 2nd drug if target not met in three months
Thiazolidinediones (TZDs) - ANSWER Pioglitazone (Actos), Rosiglitazone (Avandia)
ADRs: WT gain, edema, HF
Glucagon-like peptide 1 (GLP-1) - ANSWER released in small intestine; decreases appetite
ADRs: WT loss & low hypoglycemia risk
